NOVAVAX INC (NVAX) Operating Margin
- Operating margin · 12 months: Value -56.58%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -56.58% | Operating income / revenue. Period ending 2026-06-30. $-234.13M ÷ $413.80M × 100 ≈ -56.58% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -234.13M USD | Operating Income (Loss) |
| Revenue | 413.80M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 340.31M USD | Research and Development Expense |
| Selling, general and administration | 121.22M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-234.13M | $413.80M | (m) | $340.31M | $121.22M | -56.58% |
| 2026-03-31 | $-78.15M | $596.34M | (m) | $348.86M | $138.17M | -13.10% |
| 2025-12-31 | $452.80M | $1.12B | (m) | $342.32M | $157.48M | 40.30% |
| 2025-09-30 | $307.49M | $1.06B | (m) | $370.82M | $201.70M | 28.88% |
| 2025-06-30 | $351.49M | $1.08B | (m) | $359.71M | (m) | 32.58% |
| 2025-03-31 | $411.41M | $1.25B | (m) | $387.43M | (m) | 32.79% |
| 2024-12-31 | $-248.93M | $682.16M | (m) | $391.17M | $337.19M | -36.49% |
| 2024-09-30 | $-301.42M | $885.19M | (m) | $451.49M | (m) | -34.05% |
| 2024-06-30 | $-293.03M | $987.67M | (m) | $470.55M | (m) | -29.67% |
| 2024-03-31 | $-398.57M | $996.61M | (m) | $583.08M | (m) | -39.99% |
| 2023-12-31 | $-566.51M | $983.71M | (m) | $737.50M | (m) | -57.59% |
| 2023-09-30 | $-626.82M | $1.05B | (m) | $830.65M | (m) | -59.71% |
| 2023-06-30 | $-628.38M | $1.60B | (m) | $1.03B | (m) | -39.34% |
| 2023-03-31 | $-1.17B | $1.36B | (m) | $1.10B | (m) | -85.87% |
| 2022-12-31 | $-644.74M | $1.98B | (m) | $1.24B | (m) | -32.53% |
| 2022-09-30 | $-1.23B | $1.85B | (m) | $1.94B | (m) | -66.38% |
| 2022-06-30 | $-1.41B | $1.29B | (m) | $2.04B | (m) | -108.90% |
| 2022-03-31 | $-1.27B | $1.40B | (m) | $2.33B | (m) | -90.42% |
| 2021-12-31 | $-1.69B | $1.15B | (m) | $2.53B | (m) | -147.13% |
| 2021-09-30 | $-1.04B | $1.20B | (m) | $1.97B | (m) | -86.77% |
| 2021-06-30 | $-931.26M | $1.18B | (m) | $1.86B | (m) | -78.79% |
| 2021-03-31 | $-602.45M | $919.45M | (m) | $1.32B | (m) | -65.52% |
| 2020-12-31 | $-416.72M | $475.60M | (m) | $747.03M | (m) | -87.62% |
| 2020-09-30 | $-262.57M | $204.75M | (m) | $375.17M | (m) | -128.24% |
| 2020-06-30 | $-83.62M | $50.24M | (m) | $99.69M | (m) | -166.44% |
| 2020-03-31 | $-103.25M | $18.06M | (m) | $95.26M | (m) | -571.83% |
| 2019-12-31 | $-120.58M | $18.66M | (m) | $113.84M | (m) | -646.13% |
| 2019-09-30 | $-138.39M | $15.97M | (m) | $127.92M | (m) | -866.39% |
| 2019-06-30 | $-165.30M | $21.20M | (m) | $150.63M | (m) | -779.68% |
| 2019-03-31 | $-170.63M | $28.62M | (m) | $164.76M | (m) | -596.25% |
| 2018-12-31 | $-173.92M | $34.29M | (m) | $173.80M | (m) | -507.23% |
| 2018-09-30 | $-175.19M | $38.57M | (m) | $180.04M | (m) | -454.18% |
| 2018-06-30 | $-174.92M | $39.19M | (m) | $180.57M | (m) | -446.34% |
| 2018-03-31 | $-174.40M | $35.15M | (m) | $175.29M | (m) | -496.16% |
| 2017-12-31 | $-171.71M | $31.18M | (m) | $168.44M | (m) | -550.78% |
| 2017-09-30 | $-177.97M | $26.16M | (m) | $169.88M | (m) | -680.24% |
| 2017-06-30 | $-199.65M | $21.04M | (m) | $181.00M | (m) | -948.82% |
| 2017-03-31 | $-234.68M | $16.82M | (m) | $206.64M | (m) | -1395.64% |
| 2016-12-31 | $-269.11M | $15.35M | (m) | $237.94M | (m) | -1752.84% |
| 2016-09-30 | $-293.97M | $15.81M | (m) | $262.74M | (m) | -1859.75% |
| 2016-06-30 | $-263.86M | $19.10M | (m) | $240.42M | (m) | -1381.40% |
| 2016-03-31 | $-208.19M | $30.59M | (m) | $203.25M | (m) | -680.54% |
| 2015-12-31 | $-157.24M | $36.25M | (m) | $162.64M | (m) | -433.75% |
| 2015-09-30 | $-110.00M | $37.12M | (m) | $109.18M | (m) | -296.33% |
| 2015-06-30 | $-96.59M | $38.81M | (m) | $100.48M | (m) | -248.88% |
| 2015-03-31 | $-93.62M | $33.07M | (m) | $90.81M | (m) | -283.06% |
| 2014-12-31 | $-83.69M | $30.66M | (m) | $79.44M | (m) | -272.97% |
| 2014-09-30 | $-66.28M | $32.68M | (m) | $65.26M | (m) | -202.79% |
| 2014-06-30 | $-61.77M | $29.27M | (m) | $59.99M | (m) | -211.02% |
| 2014-03-31 | $-56.81M | $24.54M | (m) | $55.57M | (m) | -231.48% |
| 2013-12-31 | $-52.43M | $20.91M | (m) | $50.31M | (m) | -250.70% |
| 2013-09-30 | $-47.68M | $16.73M | (m) | $42.78M | (m) | -284.92% |
| 2013-06-30 | $-39.24M | $17.70M | (m) | $35.48M | (m) | -221.77% |
| 2013-03-31 | $-32.20M | $21.27M | (m) | $30.16M | (m) | -151.42% |
| 2012-12-31 | $-29.66M | $22.08M | (m) | $26.06M | (m) | -134.38% |
| 2012-09-30 | $-24.43M | (m) | (m) | $21.06M | (m) | (m) |
| 2012-06-30 | $-21.55M | (m) | (m) | $18.71M | (m) | (m) |
| 2012-03-31 | $-21.62M | (m) | (m) | $17.89M | (m) | (m) |
| 2011-12-31 | $-21.58M | (m) | (m) | $17.89M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-38.49M | (m) | (m) | $28.03M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-37.38M | (m) | (m) | $25.78M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |